Present invention discloses a Lactobacillus composition comprising Lactobacillus reuteri GMNL-263 which is a strain of heat-killed dead bacteria and has the effect of lowering blood pressure by inhibition of proinflammatory cytokine IL-1 and enhancement the growth of Bifidobacterium, and said Lactobacillus composition is a pharmaceutical composition, nutritional supplement, health food or a combination thereof.

The present invention relates to a novel Lactobacillus strain that is not attacked by common phages and a novel Lactobacillus strain with improved cell count stability, its use in the manufacture of fermented milk-based products, and novel milk based products containing the strain.

Disclosed are microbial compositions having unique combinations of microbial species which are used in plant material recycling to form a nutrient source. Also disclosed microbial inoculants which contains such a microbial composition, water, and an optional carbon source. The microbial compositions and microbial inoculants are particularly useful in recycling high lignin-content plant material. Methods of making and methods of using the microbial compositions and the microbial inoculants are also described.

The probiotic composition comprises at least one lactic acid bacteria strain, preferably Lactobacillus with intestinal tropism, for use in promoting juvenile growth in livestock, with stimulation of linear growth and/or of IGF-1 level. Exemplary lactic acid bacteria include Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus casei, Lactobacillus paracasei and Lactobacillus rhamnosus. The strains can be selected in a mouse model. The invention also relates to a probiotic treatment method using this composition.

Disclosed are very high optically pure D- and L-lactic acid fermentation production strains and construction methods thereof and the method for preparing very high optically pure D- and L-lactic acids using the strains, wherein the deposit number of the D-lactic acid fermentation production strain is CGMCC No. 11059, and the deposit number of the L-lactic acid fermentation production strain is CGMCC No. 11060.

The present invention relates to a gene expression cassette including a strong promoter derived from lactic acid bacteria, and a gene expression vector including the same. According to the present invention, a large amount of a human protein, the physiological activity of which has been verified, may be stably produced with high efficiency by introducing a useful foreign gene into an expression vector and transforming probiotics with the expression vector. Through the production of this protein, it is possible to provide a basis for developing functional probiotics and making products using them.

The present invention relates to a microorganism for drug delivery, which has been transformed with a gene construct comprising a therapeutically active peptide, which can be delivered safely into the intestines through oral administration, and which can express and secrete the therapeutic peptide in the gastrointestinal tract, and also relates to a pharmaceutical composition for prevention or treatment of gastrointestinal disease, which includes the same. The present invention is directed to a lactic acid bacteria drug delivery system capable of overexpressing and secreting a lactic acid bacteria-derived anticancer protein, which is developed by introducing the anticancer protein into a lactic acid bacteria expression and secretion system. It is expected that the lactic acid bacteria drug delivery system will be widely used as a natural protein therapeutic agent against gastrointestinal disease in the medical field.

The aim of the present invention is a method for the preparation of anallergic probiotic bacterial cultures.

Vacuum infusion of plant extracts in live probiotic cells significantly enhances the viability of probiotics during in vitro gastrointestinal digestion with the retention of their metabolic and antagonistic activities. In-vivo results validate the significantly enhanced persistence and mucoadhesion of probiotic cells with infused plant extracts.

The present disclosure relates to a strain of Lactobacillus gasseri LM1065 (KCCM13018P) and a composition of relieving premenstrual syndrome containing the strain.

A strain of Lactobacillus gasseri LM1065 (KCCM13018P) according to an embodiment of the present disclosure can relieve premenstrual syndrome by reducing NO in blood and TL-6 gene expression and increasing the production ratio of prostaglandin E1/prostaglandin E2 in blood and DGLA levels. Therefore, the strain can be applied to food compositions, health functional food compositions, pharmaceutical compositions, and the like.